238 related articles for article (PubMed ID: 37156252)
21. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.
Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J
Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132
[TBL] [Abstract][Full Text] [Related]
22. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Tuttle KR; Lakshmanan MC; Rayner B; Busch RS; Zimmermann AG; Woodward DB; Botros FT
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):605-617. PubMed ID: 29910024
[TBL] [Abstract][Full Text] [Related]
23. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
[TBL] [Abstract][Full Text] [Related]
24. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.
Blonde L; Jendle J; Gross J; Woo V; Jiang H; Fahrbach JL; Milicevic Z
Lancet; 2015 May; 385(9982):2057-66. PubMed ID: 26009229
[TBL] [Abstract][Full Text] [Related]
25. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
26. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
27. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
[TBL] [Abstract][Full Text] [Related]
28. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Zinman B; Fulcher G; Rao PV; Thomas N; Endahl LA; Johansen T; Lindh R; Lewin A; Rosenstock J; Pinget M; Mathieu C
Lancet; 2011 Mar; 377(9769):924-31. PubMed ID: 21396703
[TBL] [Abstract][Full Text] [Related]
29. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
30. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S; Kahn SE; Pavo I; Weerakkody GJ; Yang Z; Doupis J; Aizenberg D; Wynne AG; Riesmeyer JS; Heine RJ; Wiese RJ;
Lancet; 2021 Nov; 398(10313):1811-1824. PubMed ID: 34672967
[TBL] [Abstract][Full Text] [Related]
31. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J
Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial.
Pasquel FJ; Gianchandani R; Rubin DJ; Dungan KM; Anzola I; Gomez PC; Peng L; Hodish I; Bodnar T; Wesorick D; Balakrishnan V; Osei K; Umpierrez GE
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):125-133. PubMed ID: 27964837
[TBL] [Abstract][Full Text] [Related]
33. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
34. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
35. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
Halberg IB; Lyby K; Wassermann K; Heise T; Zijlstra E; Plum-Mörschel L
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):179-188. PubMed ID: 30679095
[TBL] [Abstract][Full Text] [Related]
37. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.
Weissman PN; Carr MC; Ye J; Cirkel DT; Stewart M; Perry C; Pratley R
Diabetologia; 2014 Dec; 57(12):2475-84. PubMed ID: 25208756
[TBL] [Abstract][Full Text] [Related]
38. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
[TBL] [Abstract][Full Text] [Related]
39. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.
Rodbard HW; Visco VE; Andersen H; Hiort LC; Shu DH
Lancet Diabetes Endocrinol; 2014 Jan; 2(1):30-7. PubMed ID: 24622667
[TBL] [Abstract][Full Text] [Related]
40. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
